PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.
In this role, Jenkins will build and lead a research team focused on leveraging external innovation, capabilities, and partnerships to boost the delivery of rare disease therapies to the patients.
Jenkins worked for over 20 years in the biopharmaceutical industry. He most recently served as Senior Vice President, Head of Research & External Innovation at Ipsen (IPN.PA, I7G.F, IPSEF.P, IPSEY).
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
